Reviews/Anti CGRP Antibodies/Erenumab and blood pressure increase
Safety · CGRP-SAF-02 · v2
Different kinds of study point in different directions on whether erenumab raises blood pressure. Reports collected by the US regulator after the drug went on sale described patients whose blood pressure rose, and this led the FDA to add hypertension to the drug's label [17]; a follow-up study that measured patients over a year found their blood pressure went up on average [27], and smaller real-world groups recorded occasional blood-pressure events [33][34]. Against this, the carefully controlled trials used for approval found blood-pressure problems no more often than with dummy injections [19], and a recent study tracking patients for up to two years found their blood pressure stayed in the normal range [21]. Laboratory work in animals supports the idea that blocking this pathway could raise blood pressure [37][38], but one animal study using an antibody found no change at all [32]. The panel judged that a loose link exists and is recognised by regulators, while the controlled data show any effect is small, inconsistent, or absent, which is why it did not treat the link as firmly established.
The corpus shows a consistent safety signal from spontaneous reporting: 61 erenumab cases of elevated blood pressure led to the label amendment [17], and a class-wide review of 106 cases concluded the whole CGRP-blocker class now carries a hypertension warning [20]. A prospective follow-up found both systolic and diastolic pressure higher at all timepoints in the erenumab group of 109 patients, with a maximum mean systolic rise of 5.2 mm Hg [27], and two real-world cohorts recorded blood-pressure events, including a transient increase in 5.2% of patients [34] and two cases in an older-patient series [33]. The controlled evidence runs the other way: pooled randomised trials reported hypertension adverse events in 0.9% on placebo versus 0.8% and 0.2% on erenumab [19], and a registry study found pressure stable within normal ranges over 12-24 months [21]. Mechanistic rodent work supports plausibility, since α-CGRP knockout mice are hypertensive [37] and a CGRP analogue is antihypertensive [38], but an anti-CGRP antibody produced no detectable blood-pressure change in rats [32]. The contested point: The division is between uncontrolled, regulator-recognised signals ([17][20][27]) that support an association and controlled or longer-term data ([19][21]) that show the effect is small or absent. Whether the observed increases reflect a true drug effect or artefacts of uncontrolled observation (reporting bias, regression to the mean, ageing) is the point the evidence does not settle.
All 40 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Anti CGRP Antibodies, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The strongest positive evidence [17] and [20] is spontaneous/postmarketing reporting with no denominator or control, subject to reporting and channelling bias; [17] itself states the data only 'suggest an association', which cannot establish incidence or causation.
Controlled RCT data contradict the signal: in the integrated analysis [19] hypertension AEs were lower on erenumab (0.2% at 140 mg) than placebo (0.9%), with an inverse rather than dose-dependent pattern, and the profile was 'comparable to that of placebo over 12 weeks'.
Where it remains uncertain. Pooled randomised trials reported hypertension adverse events in 0.2% on erenumab 140 mg versus 0.9% on placebo [19], and a registry found blood pressure stable over 12-24 months [21], undercutting a causal or clinically meaningful reading.
Aleatory
Even where increases are seen, the mean systolic rise is modest (5.2 mm Hg [27]) and most patients stay within normal limits [27][21], so individual responses vary widely around a small average.
The load-bearing papers from a corpus of 40, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Regulatory-grade pharmacovigilance signal (61 cases, median SBP increase 39 mm Hg) that drove the erenumab label change — primary support for the association.
“This case series suggest an association between elevated BP and use of erenumab. In light of our findings, the erenumab (Aimovig) prescribing information was amended to include hypertension in the Warnings and Precautions section.”
Panel auditInternal validity: low · scope of inference: Spontaneously reported elevated-BP events during erenumab use.Key limitations: uncontrolled spontaneous reports · no denominator · selection and reporting bias
Independent confirmation that the erenumab-hypertension signal is regulator-recognised and situates it in a class-wide effect.
“The US Food and Drug Administration (FDA) previously identified postmarketing case reports of hypertension associated with erenumab resulting in an amendment of the US Prescribing Information.”
Panel auditInternal validity: low · scope of inference: Hypertension reports for CGRP-L/R blockers other than erenumab.Key limitations: excludes erenumab · uncontrolled reports · no denominator
Prospective real-world measurement showing a statistically significant erenumab-specific BP increase; strongest measured (non-spontaneous) positive evidence.
“In the erenumab group (n = 109), both systolic and diastolic BP were increased at all time points compared with T0 (all p < 0.001).”
Panel auditInternal validity: medium · scope of inference: Within-patient BP change after starting erenumab in real-world migraine care.Key limitations: no placebo control · before-after design · regression-to-mean and secular trends unaddressed
Controlled RCT counter-evidence: hypertension AEs comparable to (or below) placebo over 12 weeks, bounding the magnitude of any association.
“Hypertension AEs were reported for 0.9% (placebo), 0.8% (erenumab 70 mg), and 0.2% (erenumab 140 mg) of patients.”
Panel auditInternal validity: high · scope of inference: Vascular and hypertension AEs with erenumab over 12 weeks in migraine trials.Key limitations: short controlled window · AE incidence not systematic BP measurement · trial-population selection
4 of 40 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The weak 'associated with' claim is well supported by regulator-recognised and prospective data, but null controlled/registry evidence caps confidence below Established.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Controlled BP as a prespecified endpoint. The positive prospective data [27] have no control arm and the controlled trials [19] report only adverse-event counts, so no study cleanly isolates an erenumab blood-pressure effect. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised placebo-controlled trial or ambulatory-BP study with blood pressure change as the prespecified primary endpoint in erenumab-treated migraine patients.
Open question: Does erenumab cause a true increase in blood pressure relative to a concurrent control? Why it is still open: The only positive prospective data are single-arm before-and-after [27]; the controlled trials report adverse-event tallies rather than measured BP change [19].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19